Related references
Note: Only part of the references are listed.Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy
Allison Barz Leahy et al.
BLOOD (2022)
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report
Liora M. Schultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M. Myers et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium
Swantje Buchmann et al.
BLOOD (2022)
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
Amy Moskop et al.
BLOOD ADVANCES (2022)
A Phase 2 Study to Test the Feasibility Safe and Efficacy of the Addition of Blinatumomab to the Interfanto6 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network
Inge M. Van Der Sluis et al.
BLOOD (2021)
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
Marie-Emilie Dourthe et al.
LEUKEMIA (2021)
Blinatumomab for infant acute lymphoblastic leukemia
Katherine Clesham et al.
BLOOD (2020)
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial
Daisuke Tomizawa et al.
BLOOD (2020)
Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme
Sara Ghorashian et al.
BLOOD (2020)
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Marcelo C. Pasquini et al.
BLOOD ADVANCES (2020)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
Colleen Annesley et al.
BLOOD (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai et al.
BLOOD ADVANCES (2019)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
E. M. C. Driessen et al.
LEUKEMIA (2016)
Lineage switch in childhood acute leukemia: An unusual event with poor outcome
Jorge G. Rossi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
Rob Pieters et al.
LANCET (2007)